Tumour localisation with polyclonal antibodies directed against CEA, in xenografts of human colon carcinomas, was first demonstrated by Primus et al. (1973) and Goldenberg et al. (1974) using organ counting and photoscanning techniques. More recently studies demonstrating successful localisation (Colcher et al., 1983; Herlyn et al., 1983 and Pimm & Baldwin, 1984) and immuno-radiotherapy (Zalcberg, 1984) in the human tumour xenograft using monoclonal antibodies against various tumour markers have been reported. In most studies the paired labelling technique of Pressman et al. (1957) has been adopted enabling the dynamics of distribution and clearance of specific anti-tumour antibodies to be compared with normal immunoglobulin. The xenograft model is particularly useful for providing a measure of the potential of the antibody for both diagnostic imaging of tumours and for therapy since it indicates the amount of specific antibody retained by tumour and its residence time. This helps to define its effective half-life and dosimetry for optimal therapeutic administration.
In the present work, described here in preliminary form, we have used the paired distribution method to evaluate a monoclonal antibody (1H12) which is directed against CEA. This IgG-1 antibody has been chosen for its high specificity for CEA and lack of cross-reactivity with human granulocytes and red cells. In this respect it is similar to the monoclonal antobody (MAb 35) described by Buchegger et al. (1983) Figure 1 . With the non-excretory tissuesstomach, colon, bone and muscle (Figure la) -a marked accumulation of H 12 occured in the first 4 h. The amount of lH12 in these organs then fell gradually to just over 1% of the injected dose by 24 h. In the same time period (1-24 h) the amount of lH12 in the blood fell from 41% to 12% of the injected dose. Similar results were obtained for the control mice (data not shown). Among the factors which are likely to determine the accumulation of 1H12 and its subsequent decline in these normal tissues are its concentration in the blood pool, the rate of transport of antibody acrosss the capillary endothelial membranes and the lymphatic drainage of antibody from the tissues.
As expected the amounts of 1H12 and normal Ig in the richly perfused organs of the reticuloendothelial system and kidney were initially much higher than in other normal tissues (Figure lb) only falling to below 1% of the injected dose by day 4. However the amounts of 1H12 in tumour exceeded the level in all normal organs except blood after day 1.
Tumour uptake of lH12 during the first 7 h was almost 5% of the injected dose, similar to that found in the non-excretory normal organs ( Figure  la) . However, whereas the concentration of IH12 in these organs fell to 1% of the injected dose by 24h, the amount in the tumour remained at the higher level. Our studies have also shown that lH12 may remain in the tumour at maximal levels at least up to 12 days after injection (Figure 2 ). During this period a gradual increase in the uptake of antibody by tumour was noted reaching 6.3% ofthe injected dose at day 9 and falling off slightly by day 12. This latent accumulation may be the result of the continued excretion or re-expression of CEA at the tumour cell surface which has been reported to take place every 6 h (Rosenthal et al., 1980) . It would however be expected to be limited by the reduced levels of I H 12 in the blood (Figure 2 ). therefore dependent on its retention by, or detention in, this tissue and not on a preferential uptake. Non-specific Ig showed a similar distribution pattern to 1H12 falling to -1% of the injected dose at 24 h in the normal organs but remaining at -1.8% in the tumour (data not shown). This is consistent with a limited localising potential previously seen with non-specific IgG (Goldenberg et al., 1974; Mach et al., 1974 Prolonged retention of a radiolabelled antitumour antibody is important since it increases the effective half-life and radiation dose received by individual tumour cells. The results reported here suggest that IH12 is a strong candidate for therapy trials. Prolonged retention of an antibody in tumour appears not to adveresely effect its clearance from normal organs. This is seen with IH12 where the tumour:blood ratio rose steadily from 0.04:1 at 1 h to over 3:1 at 12 days (Figure 3) .
Our results are similar to those reported by Colcher et al. (1984) for an unrelated antibody which remained in tumour up to 19 days after injection. This contrasts with previous reports using monoclonal antibodies to various tumour markers where optimal tumour localisation was between 3 and 7 days (Mach et al., 1974; Hedin et al., 1982; Buchegger et al., 1983; Herlyn et al., 1983 and Zalcberg et al., 1983) . In conclusion these studies have provided new information concerning the dynamics of distribution for a monoclonal anti-CEA antibody from 1 h to 12 days. It will be important to study the effect of escalating and sequential doses in relation to therapy and the results here should facilitate the design and interpretation of such experiments.
